在宫 dystonia 中,GPi-DBS 诱导的大脑代谢激活
Emma A Honkanen1,2,3,4, Jaana Rönkä1,5, Eero Pekkonen6
1Neurocenter, Turku University Hospital, Turku, Finland.
Journal of neurology, neurosurgery, and psychiatry
|September 27, 2023
概括
全球内体 (GPi) 的深度大脑刺激 (DBS) 提高了大脑的新陈代谢,特别是在运动区域. 这种代谢转变与宫性 dystonia 患者的症状改善相关.
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 神经调节是一种神经调节.
背景情况:
- 宫性 dystonia 是有效地治疗的 球体的内部深度大脑刺激 (GPi-DBS).
- 在宫 dystonia 中GPi-DBS 的确切作用机制尚不清楚.
- 研究大脑代谢变化为GPi-DBS疗效提供了洞察力.
研究的目的:
- 为了探索大脑的代谢变化诱导GPi-DBS在宫 dystonia患者.
- 为了将代谢变化与临床结果和刺激参数相关联.
主要方法:
- 18F-氧葡萄糖正子发射断层扫描 (FDG-PET) 用于11名患有GPi-DBS的患者.
- 用DBS打开和关闭来评估大脑新陈代谢,分析活动接触和整个大脑.
- 临床结果使用多伦多西部性扭曲症评分表 (TWSTRS),Trail Making Test (TMT) 和统一帕金森病评分表 (UPDRS) 来衡量.
主要成果:
- GPi-DBS显著改善了运动症状 (减少TWSTRS).
- DBS增加了GPi接触部位的新陈代谢,与刺激幅度相关.
- 全脑分析显示,GPi,亚thalamic核,膜和感觉运动皮层的新陈代谢增加.
- 感觉运动皮层中的代谢激活与急性症状改善相关.
- 副作用 (认知和帕金森症状) 与前带皮层和前带皮层的代谢变化有关.
结论:
- GPi-DBS增强了内部球和感觉运动网络中的代谢活动.
- GPi-DBS的临床益处和副作用与特定神经网络的调制有关.
更多相关视频
10:41Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
7.4K
09:36In vivo Positron Emission Tomography to Reveal Activity Patterns Induced by Deep Brain Stimulation in Rats
Published on: March 23, 2022
2.2K
相关概念视频
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...